Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

B Coster

Showing results (1-10 of 9) with videos related to

Pageof 1
Sort By:
Acta Chirurgica Belgica|November 1, 1988
[A case of post-mastectomy lymphangiosarcoma]B Coster, A Schmitz, C Six, et al.
Acta Orthopaedica Belgica|January 1, 1989
[Soft-tissue sarcomas. Review of 47 patients treated in 10 years in the same institute]B Coster, A Schmitz, C Six, et al.
Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology|January 1, 1993
Influence of cisplatinum on intestinal tolerance to photon and neutron irradiation in miceP Lambin, P Scalliet, B Coster, et al.
American Journal of Perinatology|October 1, 1990
Isolated fetal ascites: prenatal diagnosis and managementH N Winn, R Stiller, P A Grannum, et al.
American Journal of Obstetrics and Gynecology|August 1, 1989
The prevalence and biologic significance of lupus anticoagulant and anticardiolipin antibodies in a general obstetric populationC J Lockwood, R Romero, R F Feinberg, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 1, 1989
Increased risk of lung cancer, non-Hodgkin's lymphoma, and leukemia following Hodgkin's diseaseF E van Leeuwen, R Somers, B G Taal, et al.
Clinical Oncology (Royal College of Radiologists (Great Britain))|December 11, 1999
Efficacy of an ondansetron orally disintegrating tablet: a novel oral formulation of this 5-HT(3) receptor antagonist in the treatment of fractionated radiotherapy-induced nausea and emesis. Emesis Study Group for the Ondansetron Orally Disintegrating Tablet in Radiotherapy TreatmentJ P LeBourgeois, C J McKenna, B Coster, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|October 13, 2005
Phase II study of preoperative oxaliplatin, capecitabine and external beam radiotherapy in patients with rectal cancer: the RadiOxCape studyJ-P Machiels, L Duck, B Honhon, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|January 9, 2007
Phase I/II study of preoperative cetuximab, capecitabine, and external beam radiotherapy in patients with rectal cancerJ-P Machiels, C Sempoux, P Scalliet, et al.
Pageof 1

Showing results (1-10 of 9) with videos related to

Sort By:
Pageof 1
Acta Chirurgica Belgica|November 1, 1988
[A case of post-mastectomy lymphangiosarcoma]B Coster, A Schmitz, C Six, et al.
Acta Orthopaedica Belgica|January 1, 1989
[Soft-tissue sarcomas. Review of 47 patients treated in 10 years in the same institute]B Coster, A Schmitz, C Six, et al.
Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology|January 1, 1993
Influence of cisplatinum on intestinal tolerance to photon and neutron irradiation in miceP Lambin, P Scalliet, B Coster, et al.
American Journal of Perinatology|October 1, 1990
Isolated fetal ascites: prenatal diagnosis and managementH N Winn, R Stiller, P A Grannum, et al.
American Journal of Obstetrics and Gynecology|August 1, 1989
The prevalence and biologic significance of lupus anticoagulant and anticardiolipin antibodies in a general obstetric populationC J Lockwood, R Romero, R F Feinberg, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 1, 1989
Increased risk of lung cancer, non-Hodgkin's lymphoma, and leukemia following Hodgkin's diseaseF E van Leeuwen, R Somers, B G Taal, et al.
Clinical Oncology (Royal College of Radiologists (Great Britain))|December 11, 1999
Efficacy of an ondansetron orally disintegrating tablet: a novel oral formulation of this 5-HT(3) receptor antagonist in the treatment of fractionated radiotherapy-induced nausea and emesis. Emesis Study Group for the Ondansetron Orally Disintegrating Tablet in Radiotherapy TreatmentJ P LeBourgeois, C J McKenna, B Coster, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|October 13, 2005
Phase II study of preoperative oxaliplatin, capecitabine and external beam radiotherapy in patients with rectal cancer: the RadiOxCape studyJ-P Machiels, L Duck, B Honhon, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|January 9, 2007
Phase I/II study of preoperative cetuximab, capecitabine, and external beam radiotherapy in patients with rectal cancerJ-P Machiels, C Sempoux, P Scalliet, et al.
Pageof 1